ABSTRACT
Pleuropulmonary fibrosis is a rare, but well-recognized adverse effect of ergot alkaloids. We report on four patients who developed pleural and/or pulmonary fibrosis during treatment with pergolide and give characteristics of 87 cases with one or more symptoms of serosal fibrosis. Retroperitoneal and pleuropulmonary fibrosis are serious conditions, which are often irreversible after drug withdrawal. Increased awareness may help to diagnose these complications at an earlier stage and to minimize any permanent damage to the patient.
Subject(s)
Dopamine Agonists/adverse effects , Pergolide/adverse effects , Pleural Diseases/chemically induced , Pulmonary Fibrosis/chemically induced , Aged , Dopamine Agonists/therapeutic use , Humans , Male , Middle Aged , Parkinson Disease/drug therapy , Pergolide/therapeutic use , Pleural Diseases/diagnostic imaging , Pulmonary Fibrosis/diagnostic imaging , Retroperitoneal Fibrosis/chemically induced , Retroperitoneal Fibrosis/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Modern antituberculous therapy consists of a combination of several drugs, some of which (e.g. rifampicin and streptomycin) may cause impairment of renal function. Pyrazinamide therapy has been associated with dose-dependent hepatotoxicity, hyperuricaemia, arthralgia and arthritis. The patient described in this report developed renal failure, fever, arthritis and arthralgia during administration of isoniazid, rifampicin, streptomycin and pyrazinamide. The renal biopsy showed tubulo-interstitial nephritis. After withdrawal of pyrazinamide, while continuing all other drugs, both renal function and histological findings improved which points to an association of renal failure with pyrazinamide.
Subject(s)
Nephritis, Interstitial/chemically induced , Pyrazinamide/adverse effects , Acute Kidney Injury/chemically induced , Adult , Humans , Male , Tuberculosis, Pulmonary/drug therapyABSTRACT
The effect of local pretreatment with ipratropium versus placebo aerosol on nasal methacholine challenge was studied in a double-blind, crossover trial. Fourteen allergic and ten non-allergic patients suffering from rhinitis participated in this study. It can be concluded that intranasal administration of ipratropium has a suppressive effect on hypersecretion and sneezing, but has no influence on nasal airway resistance.
